The glucagon-like peptide-1 (GLP-1) receptor sits at the centre of contemporary metabolic research. This article gives a working overview of the receptor, the single, dual and triple agonist research peptides currently in widespread use, and the experimental questions each is best suited to address.
The receptor
GLP-1R is a class B G-protein-coupled receptor expressed primarily in pancreatic β-cells, intestinal L-cells, the central nervous system (notably the area postrema and arcuate nucleus), the heart and the kidneys. Its endogenous ligand, GLP-1(7–36) amide, is secreted from L-cells in response to nutrient ingestion and has a half-life of 1–2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4).
Activation drives Gαs–cAMP signalling, downstream PKA and Epac activity, and — pharmacologically — β-cell glucose-dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and central reduction of food intake.
The pharmacology problem
The endogenous peptide is too short-lived for clinical or chronic-research use. Research peptides solve this through:
- DPP-4 resistance — substitution of Ala-2 with α-aminoisobutyric acid (Aib) blocks DPP-4 cleavage.
- Albumin binding — fatty-acid acylation (a C16 or C18 chain via a γGlu/2×OEG linker) extends half-life from minutes to days.
- Receptor co-engagement — adding agonism at GIP and/or glucagon receptors broadens metabolic effect.
The research-relevant peptides
Semaglutide
A long-acting GLP-1 mono-agonist with Aib²-substitution and a C18 fatty diacid chain attached at Lys²⁶. Half-life ~165 hours in human; in research models, suitable for once-weekly dosing paradigms. Used for:
- β-cell function studies.
- Central appetite regulation.
- Hepatic steatosis models.
- Cardiovascular outcome research.
Tirzepatide
A dual GIP/GLP-1 receptor agonist on a single 39-residue scaffold. Greater weight-loss efficacy than semaglutide in head-to-head pre-clinical work; the GIP component contributes to lipid metabolism beyond GLP-1 alone. Useful when distinguishing GLP-1-only from GIP-augmented effects.
Retatrutide
A triple GIP / GLP-1 / glucagon receptor agonist. The glucagon component adds direct hepatic energy expenditure to the GLP-1/GIP-driven appetite and insulinotropic effects. Primarily of interest in obesity and NASH research models where increased basal energy expenditure is a desired endpoint.
Cagrilintide
An amylin analogue, not a GLP-1 agonist, but co-administered with semaglutide in many recent metabolic studies (the “CagriSema” combination). Acts at the amylin and calcitonin receptors to suppress gastric emptying and food intake by a parallel mechanism.
Choosing between them
| Question | Most informative peptide |
|---|---|
| Is the effect GLP-1-receptor-mediated only? | Semaglutide |
| Does GIP co-agonism add to the GLP-1 effect? | Tirzepatide vs semaglutide |
| Does glucagon agonism add hepatic energy expenditure? | Retatrutide vs tirzepatide |
| Is the appetite effect dependent on amylin signalling? | Semaglutide ± cagrilintide |
| Is DPP-4 resistance sufficient or is acylation also required for the model timescale? | Aib²-only analogue vs acylated analogue |
Methodological notes
- Reconstitution. All four peptides reconstitute readily in bacteriostatic water at 2–10 mg/mL. Avoid PBS at high concentration — visible cloudiness can occur.
- Half-life in animal models. Mouse and rat clearance is faster than human; published dose translation tables differ by 5–20× between species.
- Receptor selectivity. When working in a primary tissue, confirm receptor expression by qPCR or IHC before attributing an effect to GLP-1R; off-target effects at GIPR and GCGR are non-trivial for tirzepatide and retatrutide.